Oramed
$3.0 million
November 2025
Bridge loan agreement under which Oramed provided the Company a $3.0 million bridge loan, fully repaid March 25, 2026.
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Bridge loan agreement under which Oramed provided the Company a $3.0 million bridge loan, fully repaid March 25, 2026.
Senior secured convertible notes and warrants issued under financing arrangements in connection with the Oratech Acquisition, with notes, warrants and pre-funded warrants amended and restated on June 30, 2026.
Clinical trial management agreement under which Oramed provides clinical-development, project-management, regulatory and operational-support services, recognized as research and development expense.
Amendment and Supplement Agreement providing equity compensation in the form of stock options for excess and additional consulting services provided in 2022 through 2024.
Exclusive distribution agreement with CorLife for the ReWalk Personal Exoskeleton for individuals with workers' compensation claims.
Loading...
